Related Experiment Video
Updated: Aug 21, 2026
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy
Samuel Truniger1, David Waber2, Joel Dütschler1
1Department of Gastroenterology and Hepatology, HOCH Health Ostschweiz, St. Gallen, Switzerland.
Background:
Reliable biomarkers to distinguish ulcerative colitis (UC) from Crohn's disease (CD) remain limited.
Aims:
To assess the diagnostic accuracy of anti-integrin αvβ6 autoantibodies for differentiating UC from CD and to compare their performance with anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA).
Methods:
In this prospective cross-sectional study in patients with UC and CD, serum anti-integrin αvβ6 autoantibodies, ASCA, and ANCA were measured and clinical data were collected. The primary outcome was the accuracy of anti-integrin αvβ6 antibodies in distinguishing UC from CD. Secondary analyses compared their performance with ASCA and ANCA status and across IBD subgroups.
Results:
A total of 224 patients were included (UC: n = 106, CD: n = 118, male: 63.8%, median age: 43.5 years). Patients with indeterminate colitis were excluded. At a cut-off of 2.44 U/mL, anti-integrin αvβ6 autoantibodies demonstrated a diagnostic accuracy of 86.5%, with a sensitivity of 85.8% and specificity of 87.1%. In a multivariate logistic regression analysis, these autoantibodies were independently associated with UC (OR 36.18, 95% CI 17.0-83.0, p = 4.86 × 10-19) and demonstrated superior diagnostic performance compared to ANCA and ASCA status (Akaike information criterion 184.8 vs. 252.4). Positivity rates followed a gradient across the Montreal classification, increasing from ileal (L1: 7.9%) and ileocolonic (L3: 8.1%) CD towards colonic CD (L2: 43.8%) and UC: 85.8% (p = 2.04 × 10-31).
Conclusions:
Anti-integrin αvβ6 autoantibodies demonstrate high diagnostic accuracy and outperform conventional serological markers in distinguishing UC from CD. Importantly, this study provides the first direct comparison with ANCA and ASCA status within the same patient cohort.
Related Concept Videos
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...